Status:

COMPLETED

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Lead Sponsor:

William Sikov MD

Collaborating Sponsors:

Yale University

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

In the MDACC/BrUOG neoadjuvant trial with weekly paclitaxel followed by Fluorouracil Plus Doxorubicin and Cyclophosphamide (FAC), the pathologic complete response (pCR) rate in HER2(-) patients was 20...

Detailed Description

See above brief summary

Eligibility Criteria

Inclusion

  • Eligibility criteria
  • Inclusion criteria:
  • Histologically documented adenocarcinoma of the breast
  • ANC \> 1000 cells
  • Female; age \> 18
  • Zubrod PS 0-1
  • Platelets \> 100,000
  • Stage IIA-IIIB disease
  • Total bilirubin \< 1.5 ULN
  • No evidence of any metastatic disease
  • Serum Creatinine \< 1.5 gm/dl
  • No prior systemic therapy for breast cancer or Creat Cl \> 30 ml/min
  • Not pregnant or lactating
  • Serum ALT \< 2.0 ULN
  • ER, PR and HER2 status required
  • LVEF (MUGA/echo WNL)
  • No baseline \> 2 neuropathy
  • Urine protein: creat ratio \< 1.0
  • HER2-negative - either IHC 0-1+ or FISH ratio \< 2.0
  • Hemoglobin \> 9 gm/dl
  • (FISH testing is required for all HER2 2-3+ tumors by IHC)
  • Exclusion criteria:
  • No Histologically documented adenocarcinoma of the breast
  • No-ANC \> 1000 cells
  • Female; age \< 18
  • Zubrod PS \> 0-1
  • Platelets \< 100,000
  • Stage IV disease
  • Total bilirubin \> 1.5 ULN
  • metastatic disease
  • Serum Creatinine \> 1.5 gm/dl
  • prior systemic therapy for breast cancer or Creat Cl \> 30 ml/min
  • pregnant or lactating
  • Serum ALT \> 2.0 ULN baseline \> 2 neuropathy
  • Urine protein: creat ratio \>1.0
  • HER2-positive
  • Hemoglobin \< 9 gm/dl

Exclusion

    Key Trial Info

    Start Date :

    September 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 15 2014

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00723125

    Start Date

    September 1 2008

    End Date

    May 15 2014

    Last Update

    April 29 2021

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    Bridgeport Hospital

    Bridgeport, Connecticut, United States, 06610

    2

    Yale Smilow Cancer Center

    New Haven, Connecticut, United States, 06519

    3

    Rhode Island Hsopital

    Providence, Rhode Island, United States, 02903

    4

    Women and Infants

    Providence, Rhode Island, United States, 02905